Found 41 matching trials
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission PHASE4 This study will establish whether prolonged chronic dosing with secukinumab...
Show More Status
Active Not Recruiting
Location
Novartis Investigative Site
Learn More & Join Trial
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) PHASE3 The purpose of this study was to demonstrate efficacy of autoinjector admin...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement PHASE3 The purpose of this study is to demonstrate the efficacy and safety of secu...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
PsA Secukinumab XCT Structural Progression Study PHASE4 Psoriatic arthritis is related with chronic inflammation and progressive ra...
Show More Location
Department of Medicine and Therapeutics
Learn More & Join Trial
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) PHASE3 The core and extension studies assessed the safety and efficacy of secukinu...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis PHASE3 The purpose of this study was to assess the clinical efficacy, safety and t...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes PHASE3 The primary objective of this study was to evaluate safety and tolerability...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. PHASE4 Psoriasis is one of the most common immune-mediated inflammatory disorders ...
Show More Location
Jinnah Post graduate Medical centre
Learn More & Join Trial
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year PHASE3 This study will assess the safety and efficacy of secukinumab compared to p...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms N/A The investigators seek clinically actionable understanding of the mechanism...
Show More Location
Queen Elizabeth University Hospital
Learn More & Join Trial